Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Basic principles and technologies for deciphering the genetic map of cancer.

Voidonikolas G, Kreml SS, Chen C, Fisher WE, Brunicardi FC, Gibbs RA, Gingras MC.

World J Surg. 2009 Apr;33(4):615-29. doi: 10.1007/s00268-008-9851-y. Review.

2.

Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.

Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D.

PLoS One. 2012;7(10):e43192. doi: 10.1371/journal.pone.0043192.

3.

Optimizing methods for the diagnosis of pancreatic cancer.

Brugge WR.

J Clin Gastroenterol. 2007 Nov-Dec;41(10):869-70. No abstract available.

PMID:
18090153
4.

Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy.

Embuscado EE, Laheru D, Ricci F, Yun KJ, de Boom Witzel S, Seigel A, Flickinger K, Hidalgo M, Bova GS, Iacobuzio-Donahue CA.

Cancer Biol Ther. 2005 May;4(5):548-54.

5.

Pancreatic adenocarcinoma.

Ryan DP, Hong TS, Bardeesy N.

N Engl J Med. 2014 Sep 11;371(11):1039-49. doi: 10.1056/NEJMra1404198. Review. No abstract available.

PMID:
25207767
6.

Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis.

Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Strzelczyk J, Janiak A, Kulig A, Malecka-Panas E.

J Physiol Pharmacol. 2004 Jul;55 Suppl 2:129-38.

7.

Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines.

Goecks J, El-Rayes BF, Maithel SK, Khoury HJ, Taylor J, Rossi MR.

Cancer Med. 2015 Mar;4(3):392-403. doi: 10.1002/cam4.360.

8.

Efficient targeted resequencing of human germline and cancer genomes by oligonucleotide-selective sequencing.

Myllykangas S, Buenrostro JD, Natsoulis G, Bell JM, Ji HP.

Nat Biotechnol. 2011 Oct 23;29(11):1024-7. doi: 10.1038/nbt.1996.

9.

Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection.

Shi C, Fukushima N, Abe T, Bian Y, Hua L, Wendelburg BJ, Yeo CJ, Hruban RH, Goggins MG, Eshleman JR.

Cancer Biol Ther. 2008 Mar;7(3):353-360.

PMID:
18075308
10.

Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.

Schleifman EB, Tam R, Patel R, Tsan A, Sumiyoshi T, Fu L, Desai R, Schoenbrunner N, Myers TW, Bauer K, Smith E, Raja R.

PLoS One. 2014 Mar 21;9(3):e90761. doi: 10.1371/journal.pone.0090761. Erratum in: PLoS One. 2014;9(4):e96019.

11.

Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.

Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJ, Goodrow T, Wood M, Obara T, Heath CW, Lynch H.

Cancer. 1997 Feb 15;79(4):700-16.

PMID:
9024708
12.

Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods.

Araki T, Shimizu K, Nakamura K, Nakamura T, Mitani Y, Obayashi K, Fujita Y, Kakegawa S, Miyamae Y, Kaira K, Ishidao T, Lezhava A, Hayashizaki Y, Takeyoshi I, Yamamoto K.

J Mol Diagn. 2010 Jan;12(1):118-24. doi: 10.2353/jmoldx.2010.090081.

13.

Intraductal tubular carcinoma of the pancreas: case report with molecular analysis.

Furukawa T, Hatori T, Fukuda A, Fujita I, Yamamoto M.

Pancreas. 2009 Mar;38(2):235-7. doi: 10.1097/MPA.0b013e318175e3e0. No abstract available.

PMID:
19238030
14.

Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues.

van Eijk R, van Puijenbroek M, Chhatta AR, Gupta N, Vossen RH, Lips EH, Cleton-Jansen AM, Morreau H, van Wezel T.

J Mol Diagn. 2010 Jan;12(1):27-34. doi: 10.2353/jmoldx.2010.090028.

15.

K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value.

Magistrelli P, Neri M, Granone P, Cesario A, Paleari L, Russo P.

Pancreas. 2008 Jul;37(1):101-2. doi: 10.1097/MPA.0b013e31815e72bc. No abstract available.

PMID:
18580451
16.

Shining the spotlight on shed KRAS in pancreatic cancer.

Sempere LF, Korc M.

Cancer Biol Ther. 2008 Mar;7(3):361-3. No abstract available.

PMID:
18614859
17.

Rapid screening assay for KRAS mutations by the modified smart amplification process.

Tatsumi K, Mitani Y, Watanabe J, Takakura H, Hoshi K, Kawai Y, Kikuchi T, Kogo Y, Oguchi-Katayama A, Tomaru Y, Kanamori H, Baba M, Ishidao T, Usui K, Itoh M, Cizdziel PE, Lezhava A, Ueda M, Ichikawa Y, Endo I, Togo S, Shimada H, Hayashizaki Y.

J Mol Diagn. 2008 Nov;10(6):520-6. doi: 10.2353/jmoldx.2008.080024.

18.

Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.

Boldrini L, Alì G, Gisfredi S, Ursino S, Baldini E, Melfi F, Lucchi M, Comin CE, Maddau C, Tibaldi C, Camacci T, Servadio A, Mussi A, Fontanini G.

Oncol Rep. 2009 Oct;22(4):683-91.

PMID:
19724844
19.

Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.

Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, Yakut T, Urer N.

Tumori. 2007 Sep-Oct;93(5):473-7.

20.

Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines.

Gysin S, Rickert P, Kastury K, McMahon M.

Genes Chromosomes Cancer. 2005 Sep;44(1):37-51.

PMID:
15929091
Items per page

Supplemental Content

Support Center